Clinical Trial Update: Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants [Phase 1]

View source ↗

Summary

Biogen completed a Phase 1 study to determine the absolute bioavailability of a single fixed subcutaneous dose of aducanumab in healthy participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Aducanumab (aducanumab)

Snippet

Sponsor: Biogen | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED